Results of phase 3 CONDOR study could have a far-reaching impact on patients with prostate cancer.
The University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.
Results showed that once daily relugolix established superiority over leuprolide and reduced the incidence of major cardiovascular events.